The Theoretical Substantiation of the Targeted Search for New DPP4 Inhibitors. Computational Studies of Potential Candidates

Authors

DOI:

https://doi.org/10.24959/ophcj.24.302677

Keywords:

gliptins, dipeptidyl peptidase-4 (DPP4), virtual screening, ADMET, molecular docking

Abstract

Growing evidence suggests that dipeptidyl peptidase 4 (DPP4) inhibitors, in addition to their role in improving glycemic control, help to reduce endothelial dysfunction and have hypolipidemic, anti-atherosclerotic, antitumor, antiviral, and neurotropic properties. This multi-target property may be one of the reasons for repurposing therapeutic treatment strategies with existing agents and the basis for finding new agents to inhibit this target. Based on the structural prerequisites and the evolutionary path of creating DPP4 inhibitors, an inhibitory (R)-β-aminoamide base was used as the basis for constructing potential candidates. It contained a substituted piperazine-2-one derivative and (S)-pyrrolidine-2-carbonitrile fragment, as well as phenyl and diphenyl rings, which were additionally saturated with substituents of various electronic structures, in position 4 of the β-aminoamide chain. The construction of the molecules was carried out taking into account the correspondence of chiral centers to combinations of chiral chains at the DPP4 binding site to possibly prevent a decrease in the inhibitory activity. In silico assessment of the “drug-likeness” and pharmacokinetic profile of the group of compounds studied showed that it had favorable characteristics and could be recommended for further molecular docking in order to predict the likely inhibition of the catalytic activity of DPP4. According to the results of docking, molecules with a moderate and high affinity were found. A detailed analysis of the resulting complexes showed that only nine compounds had a binding mode similar to classical inhibitors. According to the calculated array of values and analysis of the results of docking among the derivatives tested, a hit compound was found as a promising DPP4 inhibitor.

Supporting Agency

  • The authors received no specific funding for this work.

Downloads

Download data is not yet available.

References

  1. Klemann, C.; Wagner, L.; Stephan, M; von Hörsten, S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4′s (DPP4) entanglement in the immune system. Clin. Exp. Immunol. 2016, 185, 1-21. https://doi.org/10.1111/cei.12781.
    |
  2. Gilbert, M. P; Pratley, R. E. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Frontiers in Endocrinology 2020, 11, 178. https://doi.org/10.3389/fendo.2020.00178.
    |
  3. Vincenzo, F.; Manfredi, T.; Carmine, C.; Mario, R. CD26: a multi-purpose pharmacological target. Curr. Clin. Pharmacol. 2014, 9 (2), 157-164. https://doi.org/10.2174/1574884708666131111201654.
    |
  4. An update on the 'gliptins'. Drug and Therapeutics Bulletin 2016, 54 (12), 138-141. https://doi.org/10.1136/dtb.2016.12.0442.
    |
  5. Ahmad, E.; Lim, S.; Lamptey, R.; Webb, D. R.; Davies, M. J. Type 2 diabetes. Lancet 2022, 400 (10365), 1803-1820. https://doi.org/10.1016/S0140-6736(22)01655-5.
    |
  6. Brunton, S. Pathophysiology of Type 2 Diabetes: The Evolution of Our Understanding. The Journal of Family Practice 2016, 65 (4 Suppl).
  7. Yazbeck, R.; Jaenisch, S. E.; Abbott, C. A. Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity? Biochem. Pharmacol. 2021, 188, 114517. https://doi.org/10.1016/j.bcp.2021.114517.
    |
  8. Liu, H.; Guo, L.; Xing, J.; Li, P.; Sang, H.; Hu, X.; Du, Y.; Zhao, L.; Song, R.; Gu, H. The protective role of DPP4 inhibitors in atherosclerosis. Eur. J. Pharmacol. 2020, 875, 173037. https://doi.org/10.1016/j.ejphar.2020.173037.
    |
  9. Hu, X.; Wang, X.; Xue, X. Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases. Molecules 2022, 27 (14), 4498. https://doi.org/10.3390/molecules27144498.
    |
  10. Mani, S.; Kaur, A.; Jakhar, K.; Kumari, G.; Sonar, S.; Kumar, A.; Das, S.; Kumar, S.; Kumar, V.; Kundu, R.; Pandey, A. K.; Singh, U. P.; Majumdar, T. Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections. Int. J. Biol. Macromol. 2023, 245, 125444. https://doi.org/10.1016/j.ijbiomac.2023.125444.
    |
  11. Posadas-Sánchez, R.; Sánchez-Muñoz, F.; Guzmán-Martín, C. A.; Hernández-Díaz Couder, A.; Rojas-Velasco, G.; Fragoso, J. M.; Vargas-Alarcón, G. Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity. Life Sci. 2021, 276, 119410. https://doi.org/10.1016/j.lfs.2021.119410.
    |
  12. Chalichem, N. S. S.; Gonugunta, C.; Krishnamurthy, P. T.; Duraiswamy, B. DPP4 Inhibitors Can Be a Drug of Choice for Type 3 Diabetes: A Mini Review. American Journal of Alzheimer's Disease & Other Dementias 2017, 32 (7), 444-451. https://doi.org/10.1177/1533317517722005.
    |
  13. Maanvi; Kumari, S.; Deshmukh, R. Dipeptidyl peptidase 4(DPP4) inhibitors stride up the management of Parkinson's disease. Eur. J. Pharmacol. 2023, 939, 175426. https://doi.org/10.1016/j.ejphar.2022.175426.
    |
  14. Bernstein, H. G.; Keilhoff, G.; Dobrowolny, H.; Steiner, J. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS – a critical overview. Rev. Neurosci. 2022, 34 (1), 1-24. https://doi.org/10.1515/revneuro-2022-0026.
    |
  15. Pires, D. E.; Blundell, T. L.; Ascher, D. B. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J. Med. Chem. 2015, 58 (9), 4066-4072. https://doi.org/10.1021/acs.jmedchem.5b00104.
    |
  16. Banerjee, P.; Eckert, A. O.; Schrey, A. K.; Preissner, R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018, 46 (W1), W257-W263. https://doi.org/10.1093/nar/gky318.
    |
  17. Semenets, A. P.; Suleiman, M. M.; Fedosov, A. I.; Shtrygol, S. Y.; Havrylov, I. O.; Mishchenko, M. V.; Kovalenko, S. M.; Georgiyants, V. A.; Perekhoda, L. O. Synthesis, docking, and biological evaluation of novel 1-benzyl-4-(4-(R)-5-sulfonylidene-4,5-dihydro-1H-1,2,4-triazol-3-yl)pyrrolidin-2-ones as potential nootropic agents. J. Med. Chem. 2022, 244, 114823. https://doi.org/10.1016/j.ejmech.2022.114823.
    |
  18. Semenets, A.; Suleiman, M.; Georgiyants, V.; Kovalenko, S.; Kobzar, N.; Grinevich, L.; Pokrovskii, M.; Korokin, M.; Soldatov, V.; Bunyatyan, V.; Perekhoda, L. Theoretical justification of a purposeful search of potential neurotropic drugs. ScienceRise: Pharmaceutical Science 2020, 4. 4-17. https://org/10.15587/2519-4852.2020.210042.
  19. Dowarah, J.; Singh, V. P. Anti-diabetic drugs recent approaches and advancements. Bioorg. Med. Chem. 2020, 28 (5), 115263, https://doi.org/10.1016/j.bmc.2019.115263.
    |
  20. Egan, A. G.; Blind, E.; Dunder, K.; Graeff, P. A. d.; Hummer, B. T.; Bourcier, T.; Rosebraugh, C. Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment. N. Engl. J. Med. 2014, 370 (9), 794-797. https://doi.org/10.1056/NEJMp1314078.
    |
  21. Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R.; Gwaltney, S. L. Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV. J. Med. Chem. 2007, 50(10), 2297-2300. https://doi/10.1021/jm070104l.
    |
  22. Mathur, V.; Alam, O.; Siddiqui, N.; Jha, M.; Manaithiya, A.; Bawa, S.; Sharma, N.; Alshehri, S.; Alam, P.; Shakeel F. Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents. Molecules 2023, 28 (15), 5860. https://doi.org/10.3390/molecules28155860.
    |
  23. Sneha, P.; Doss, C. G. P. Gliptins in managing diabetes – Reviewing computational strategy. Life Sci. 2016, 166, 108-120. https://doi.org/10.1016/j.lfs.2016.10.009.
    |
  24. Drwal, M. N.; Banerjee, P.; Dunkel, M.; Wettig, M. R.; Preissner, R. ProTox: a web server for the in silico prediction of rodent oral toxicity. Nucleic Acids Res. 2014, 42 (W1), W53-W58. https://doi.org/1093 1093/nar/gku401.
    |
  25. Lee, H. K.; Kim, M.-K.; Kim, H. D.; Kim, H. J.; Kim, J. W.; Lee, J.-O.; Kim, C.-W.; Kim, E. E. Unique binding mode of Evogliptin with human dipeptidyl peptidase IV. Biochem. Biophys. Res. Commun. 2017, 494 (3), 452-459. https://doi.org/10.1016/j.bbrc.2017.10.101.
    |

Downloads

Published

2024-04-07

How to Cite

(1)
Suleiman, M. M.; Semenets А. P.; Kobzar, N. P.; Perekhoda, L. O. The Theoretical Substantiation of the Targeted Search for New DPP4 Inhibitors. Computational Studies of Potential Candidates. J. Org. Pharm. Chem. 2024, 22, 3-12.

Issue

Section

Original Researches